EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S. Smolen, Robert Landewé, Johannes Bijlsma, Gerd Burmester, Katerina Chatzidionysiou, Maxime Dougados, Jackie Nam, Sofia Ramiro, Marieke Voshaar, Ronald van Vollenhoven, Daniel Aletaha, Martin Aringer, Maarten Boers, Chris D. Buckley, Frank Buttgereit, Vivian Bykerk, Mario Cardiel, Bernard Combe, Maurizio Cutolo, Yvonne van Eijk-HustingsPaul Emery, Axel Finckh, Cem Gabay, Juan Gomez-Reino, Laure Gossec, Jacques Eric Gottenberg, Johanna M.W. Hazes, Tom Huizinga, Meghna Jani, Dmitry Karateev, Marios Kouloumas, Tore Kvien, Zhanguo Li, Xavier Mariette, Iain McInnes, Eduardo Mysler, Peter Nash, Karel Pavelka, Gyula Poór, Christophe Richez, Piet van Riel, Andrea Rubbert-Roth, Kenneth Saag, Jose da Silva, Tanja Stamm, Tsutomu Takeuchi, René Westhovens, Maarten de Wit, Désirée van der Heijde

Research output: Contribution to journalReview article

734 Citations (Scopus)

Abstract

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.

Original languageEnglish
Pages (from-to)960-977
Number of pages18
JournalAnnals of the Rheumatic Diseases
Volume76
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Antirheumatic Agents
Rheumatic Diseases
Rheumatoid Arthritis
Advisory Committees
Glucocorticoids
Janus Kinases
leflunomide
Biosimilar Pharmaceuticals
Methotrexate
Hospital Societies
Sulfasalazine
Social Security
Rheumatology
Autoantibodies
Erosion
Therapeutics
Tumor Necrosis Factor-alpha
Costs and Cost Analysis
Costs

Keywords

  • Disease Activity
  • DMARDs (biologic)
  • DMARDs (synthetic)
  • Rheumatoid Arthritis
  • Treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. / Smolen, Josef S.; Landewé, Robert; Bijlsma, Johannes; Burmester, Gerd; Chatzidionysiou, Katerina; Dougados, Maxime; Nam, Jackie; Ramiro, Sofia; Voshaar, Marieke; van Vollenhoven, Ronald; Aletaha, Daniel; Aringer, Martin; Boers, Maarten; Buckley, Chris D.; Buttgereit, Frank; Bykerk, Vivian; Cardiel, Mario; Combe, Bernard; Cutolo, Maurizio; van Eijk-Hustings, Yvonne; Emery, Paul; Finckh, Axel; Gabay, Cem; Gomez-Reino, Juan; Gossec, Laure; Gottenberg, Jacques Eric; Hazes, Johanna M.W.; Huizinga, Tom; Jani, Meghna; Karateev, Dmitry; Kouloumas, Marios; Kvien, Tore; Li, Zhanguo; Mariette, Xavier; McInnes, Iain; Mysler, Eduardo; Nash, Peter; Pavelka, Karel; Poór, Gyula; Richez, Christophe; van Riel, Piet; Rubbert-Roth, Andrea; Saag, Kenneth; da Silva, Jose; Stamm, Tanja; Takeuchi, Tsutomu; Westhovens, René; de Wit, Maarten; van der Heijde, Désirée.

In: Annals of the Rheumatic Diseases, Vol. 76, No. 6, 01.06.2017, p. 960-977.

Research output: Contribution to journalReview article

Smolen, JS, Landewé, R, Bijlsma, J, Burmester, G, Chatzidionysiou, K, Dougados, M, Nam, J, Ramiro, S, Voshaar, M, van Vollenhoven, R, Aletaha, D, Aringer, M, Boers, M, Buckley, CD, Buttgereit, F, Bykerk, V, Cardiel, M, Combe, B, Cutolo, M, van Eijk-Hustings, Y, Emery, P, Finckh, A, Gabay, C, Gomez-Reino, J, Gossec, L, Gottenberg, JE, Hazes, JMW, Huizinga, T, Jani, M, Karateev, D, Kouloumas, M, Kvien, T, Li, Z, Mariette, X, McInnes, I, Mysler, E, Nash, P, Pavelka, K, Poór, G, Richez, C, van Riel, P, Rubbert-Roth, A, Saag, K, da Silva, J, Stamm, T, Takeuchi, T, Westhovens, R, de Wit, M & van der Heijde, D 2017, 'EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update', Annals of the Rheumatic Diseases, vol. 76, no. 6, pp. 960-977. https://doi.org/10.1136/annrheumdis-2016-210715
Smolen, Josef S. ; Landewé, Robert ; Bijlsma, Johannes ; Burmester, Gerd ; Chatzidionysiou, Katerina ; Dougados, Maxime ; Nam, Jackie ; Ramiro, Sofia ; Voshaar, Marieke ; van Vollenhoven, Ronald ; Aletaha, Daniel ; Aringer, Martin ; Boers, Maarten ; Buckley, Chris D. ; Buttgereit, Frank ; Bykerk, Vivian ; Cardiel, Mario ; Combe, Bernard ; Cutolo, Maurizio ; van Eijk-Hustings, Yvonne ; Emery, Paul ; Finckh, Axel ; Gabay, Cem ; Gomez-Reino, Juan ; Gossec, Laure ; Gottenberg, Jacques Eric ; Hazes, Johanna M.W. ; Huizinga, Tom ; Jani, Meghna ; Karateev, Dmitry ; Kouloumas, Marios ; Kvien, Tore ; Li, Zhanguo ; Mariette, Xavier ; McInnes, Iain ; Mysler, Eduardo ; Nash, Peter ; Pavelka, Karel ; Poór, Gyula ; Richez, Christophe ; van Riel, Piet ; Rubbert-Roth, Andrea ; Saag, Kenneth ; da Silva, Jose ; Stamm, Tanja ; Takeuchi, Tsutomu ; Westhovens, René ; de Wit, Maarten ; van der Heijde, Désirée. / EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. In: Annals of the Rheumatic Diseases. 2017 ; Vol. 76, No. 6. pp. 960-977.
@article{fe64d06353894429827e674803b6051e,
title = "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update",
abstract = "Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50{\%} improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.",
keywords = "Disease Activity, DMARDs (biologic), DMARDs (synthetic), Rheumatoid Arthritis, Treatment",
author = "Smolen, {Josef S.} and Robert Landew{\'e} and Johannes Bijlsma and Gerd Burmester and Katerina Chatzidionysiou and Maxime Dougados and Jackie Nam and Sofia Ramiro and Marieke Voshaar and {van Vollenhoven}, Ronald and Daniel Aletaha and Martin Aringer and Maarten Boers and Buckley, {Chris D.} and Frank Buttgereit and Vivian Bykerk and Mario Cardiel and Bernard Combe and Maurizio Cutolo and {van Eijk-Hustings}, Yvonne and Paul Emery and Axel Finckh and Cem Gabay and Juan Gomez-Reino and Laure Gossec and Gottenberg, {Jacques Eric} and Hazes, {Johanna M.W.} and Tom Huizinga and Meghna Jani and Dmitry Karateev and Marios Kouloumas and Tore Kvien and Zhanguo Li and Xavier Mariette and Iain McInnes and Eduardo Mysler and Peter Nash and Karel Pavelka and Gyula Po{\'o}r and Christophe Richez and {van Riel}, Piet and Andrea Rubbert-Roth and Kenneth Saag and {da Silva}, Jose and Tanja Stamm and Tsutomu Takeuchi and Ren{\'e} Westhovens and {de Wit}, Maarten and {van der Heijde}, D{\'e}sir{\'e}e",
year = "2017",
month = "6",
day = "1",
doi = "10.1136/annrheumdis-2016-210715",
language = "English",
volume = "76",
pages = "960--977",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

T2 - 2016 update

AU - Smolen, Josef S.

AU - Landewé, Robert

AU - Bijlsma, Johannes

AU - Burmester, Gerd

AU - Chatzidionysiou, Katerina

AU - Dougados, Maxime

AU - Nam, Jackie

AU - Ramiro, Sofia

AU - Voshaar, Marieke

AU - van Vollenhoven, Ronald

AU - Aletaha, Daniel

AU - Aringer, Martin

AU - Boers, Maarten

AU - Buckley, Chris D.

AU - Buttgereit, Frank

AU - Bykerk, Vivian

AU - Cardiel, Mario

AU - Combe, Bernard

AU - Cutolo, Maurizio

AU - van Eijk-Hustings, Yvonne

AU - Emery, Paul

AU - Finckh, Axel

AU - Gabay, Cem

AU - Gomez-Reino, Juan

AU - Gossec, Laure

AU - Gottenberg, Jacques Eric

AU - Hazes, Johanna M.W.

AU - Huizinga, Tom

AU - Jani, Meghna

AU - Karateev, Dmitry

AU - Kouloumas, Marios

AU - Kvien, Tore

AU - Li, Zhanguo

AU - Mariette, Xavier

AU - McInnes, Iain

AU - Mysler, Eduardo

AU - Nash, Peter

AU - Pavelka, Karel

AU - Poór, Gyula

AU - Richez, Christophe

AU - van Riel, Piet

AU - Rubbert-Roth, Andrea

AU - Saag, Kenneth

AU - da Silva, Jose

AU - Stamm, Tanja

AU - Takeuchi, Tsutomu

AU - Westhovens, René

AU - de Wit, Maarten

AU - van der Heijde, Désirée

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.

AB - Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (Janus kinase (Jak) inhibitors tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-target) and the targets of sustained clinical remission (as defined by the American College of Rheumatology-(ACR)-EULAR Boolean or index criteria) or low disease activity are discussed. Cost aspects were taken into consideration. As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. If this fails stratification is recommended. Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus short-term GC) is suggested. In the presence of unfavourable prognostic markers (autoantibodies, high disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in sustained remission, bDMARDs can be tapered. For each recommendation, levels of evidence and Task Force agreement are provided, both mostly very high. These recommendations intend informing rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.

KW - Disease Activity

KW - DMARDs (biologic)

KW - DMARDs (synthetic)

KW - Rheumatoid Arthritis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85019702082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019702082&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2016-210715

DO - 10.1136/annrheumdis-2016-210715

M3 - Review article

C2 - 28264816

AN - SCOPUS:85019702082

VL - 76

SP - 960

EP - 977

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -